← Leaderboards
Shannon Elisabeth Elf
Brigham And Women'S Hospital
$2,739,617
Attributed
$2,739,617
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $496.1K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,739,617 · 3
By mechanism
R01$1,857,077 · 1
R00$747,000 · 1
K99$135,540 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Kellie Rae Machlus$5,242,384
- Ann Mullally$5,507,634
- James A. Lederer$21,491,638
- Aleksandar Milan Babic$673,650
- Sandro Santagata$8,660,973
Others in their field
Other Emerging Leaders on “Mpl Gene”
- Xi Chen · Baylor College Of Medicine$2,535,803
- Seung Ha Nam · Weill Medical Coll Of Cornell Univ$2,490,205
- Jiliang Li · Indiana University Indianapolis$1,639,744
- Babal K Jha · Cleveland Clinic Lerner Com-Cwru$1,304,449
- Srdan Verstovsek · University Of Tx Md Anderson Can Ctr$1,168,238
- Seongseok Yun · H. Lee Moffitt Cancer Ctr & Res Inst$1,106,082
Research focus
Mpl GeneResponseGenesMolecular ChaperonesMyeloproliferative DiseaseProteinsBindingEndoplasmic Reticulum StressMediatingMolecularMutationMyeloid CellsPathogenicityPathway InteractionsCalreticulinCancer CellAcute Myelocytic LeukemiaEndoplasmic ReticulumHematopoieticCellsCell SurvivalMetabolismMutantSignal Transduction
Grant awards (8)
The Pathophysiology of Type 1 Versus Type 2 Mutant Calreticulin-Drivenmyeloproliferative Neoplasms$463,672
R01 · FY2025 · HL · contact PI
The Pathophysiology of Type 1 Versus Type 2 Mutant Calreticulin-Drivenmyeloproliferative Neoplasms$422,510
R01 · FY2024 · HL · contact PI
The pathophysiology of type 1 versus type 2 mutant calreticulin-drivenmyeloproliferative neoplasms$474,785
R01 · FY2023 · HL · contact PI
The pathophysiology of type 1 versus type 2 mutant calreticulin-drivenmyeloproliferative neoplasms$496,110
R01 · FY2022 · HL · contact PI
Mechanistic and functional dissection of myeloid blood cancers$249,000
R00 · FY2021 · HL · contact PI
Mechanistic and functional dissection of myeloid blood cancers$249,000
R00 · FY2020 · HL · contact PI
Mechanistic and functional dissection of myeloid blood cancers$249,000
R00 · FY2019 · HL · contact PI
Mechanistic and functional dissection of myeloid blood cancers$135,540
K99 · FY2018 · HL · contact PI